Cáncer renal avanzado. Manejo a propósito de un caso
- Nalda Arrija, I. 1
- Bernier García, L. 1
- Peñas Pita da Veiga, M. 1
- Cassinello Espinosa, J. 1
- 1 Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
ISSN: 0304-5412
Année de publication: 2021
Titre de la publication: Enfermedades oncológicas (III) Tumores genitourinarios
Serie: 13
Número: 26
Pages: 1491-1492
Type: Article
D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado
Objectifs de Développement Durable
Références bibliographiques
- Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progressionfree survival by independent review and overall survival update. Eur J Cancer. 2018;94:115-25.
- Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open label, phase 3 trial. Lancet Oncol. 2016;17(7):917-27.
- Escudier B, Porta C, Schmidinger M, Rioux Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2019;30:706-20.
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferón alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356(2):115-24.
- Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013;369(8):722-31.
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal cell carcino-ma. N Engl J Med. 2015;373(19):1803-1